SSStephan Staubach

Stephan Staubach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephan Staubach has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Horst Sievert

    CardioVascular Center Frankfurt Sankt Katharinen und Universitätsklinikum Frankfurt Frankfurt Germany

    2 shared publications
  • Nina Wunderlich

    CardioVascular Center Frankfurt Sankt Katharinen und Universitätsklinikum Frankfurt Frankfurt Germany

    2 shared publications
  • Daniel H. Steinberg

    CardioVascular Center Frankfurt Sankt Katharinen und Universitätsklinikum Frankfurt Frankfurt Germany

    1 shared publication
  • Gerhard Schuler

    Herzzentrum Leipzig Klinik für Kardiologie Leipzig Germany

    1 shared publication
  • German Transcatheter Aortic Valve Implantation—Registry Investigators

    1 shared publication
  • Gert Richardt

    Herz‐Kreislauf Zentrum Bad Segeberg Germany

    1 shared publication

Latest Publications

  • Progressive dyspnea and signs of right heart dysfunction

    by Stephan Staubach, Henning Strohm, Harald Mudra

    A 40-year-old woman was admitted due to dyspnea and fever. Transthoracic echocardiography revealed signs of right heart volume overload and vegetations on the tricuspid valve with insufficiency. Transesophageal echocardiography showed a sinus venosus defect (SVD) with significant left-to-right shunt. Computed tomography scanning was primarily performed to rule out pulmonary embolism; however, it showed interatrial communication. Due to the concomitant tricuspid insufficiency with additional volume overload, the diagnosis of SVD was more challenging. Usually, transthoracic echocardiography remains the initial diagnostic imaging modality; however, detection rates are very low. Therefore, further imaging is mandatory in unexplained substantial right heart dilatation.


  • Impact of aortic valve calcification on the outcome of transcatheter aortic valve implantation: Results from the prospective multicenter German TAVI registry

    by Stephan Staubach, Jennifer Franke, Ulrich Gerckens, Gerhard Schuler, Ralf Zahn, Holger Eggebrecht, Rainer Hambrecht, Stefan Sack, Gert Richardt, Martin Horack, et al.

    Objectives Transcatheter aortic valve implantation (TAVI) is an emerging technology in patients with severe aortic stenosis. Background Whether the degree of aortic valve calcification impacts the outcome after TAVI has not been thoroughly evaluated. Methods We analyzed data from the prospective multicenter German TAVI registry, including 1,365 patients as of July 2010. Patients were divided into three groups, based on the degree of aortic valve calcification: mild (n = 67), moderate (n = 392), and severe (n = 906) valve calcification, determined by visual estimation by the operator. Results Mean age was 81.7 ± 6.2 years; mean logistic EUROscore was 20.6 ± 13.7%. Patients with severe aortic valve calcification had a higher mean and peak‐to‐peak gradient before the intervention (P < 0.0001). Technical success was achieved in 97%, similar in each group. The Medtronic CoreValve was implanted in 80.8%, the Sapien Edwards prosthesis in the remaining cases. The duration of the procedure and fluoroscopy was higher in the group with severe calcification (P < 0.01 for procedure and P < 0.05 for fluoroscopy). During the periprocedural period there were no differences among the groups regarding in‐hospital death, cerebrovascular events, myocardial infarction, thromboembolic events, aortic dissection, or severe vascular complications. Furthermore, there was no significant difference in postprocedural aortic mean gradient (7.0 mm Hg vs. 5.6 mm Hg vs. 6.3 mm Hg; P = 0.07), in residual aortic regurgitation (74% vs. 72% vs. 68%; P = 0.3) or postprocedure pacemaker implantation (38% vs. 30.4% vs. 34.2%; P = 0.35). During 30‐day follow up there was no difference in regard to the number of death, strokes, and myocardial infarctions. Conclusions Our results of a real‐world registry suggest that the extent of aortic valve calcification does not influence the success or procedural outcome significantly.


  • Painful congestion of the lower limbs and recurrent fever

    by Stephan Staubach, Martin Hug, Harald Mudra

    We describe a 45-year-old patient with massive pain and congestion in the lower limbs. In addition, he daily presented fever up to 39.5°C (103.1°F) without any infectious focus for 8 days. A formerly unknown vena cava atresia with severe bilateral deep vein thrombosis and concomitant heterozygous prothrombin (factor II) gene mutation (G20210A) was diagnosed during the hospital stay. Because of the severe clinical findings and hereditary thrombophilia, we recommended a lifelong anticoagulant therapy and elastic stockings. Furthermore, different diagnosis and treatment strategies are discussed in case of concomitant prothrombin gene mutation.


  • Late complications of transcatheter closure of patent foramen ovale: new technology and new outcomes

    by Stephan Staubach, Stefan Bertog, Nina Wunderlich, Horst Sievert

    As a method to prevent recurrent paradoxical embolism and therefore cryptogenic stroke, catheter-based patent foramen ovale closure was first reported in 1992. Since then numerous different devices have been designed to prevent paradoxical embolism. The development of new devices has risen pretty rapidly. Currently, no device can be regarded as the gold standard. Prospective randomized trials comparing interventionalpatent foramen ovale closure with medical treatment are still lacking. The primary aim is to create a device which is easy to implant and able to prevent paradoxical embolism. Additional goals are to minimize early and late complications, such as thrombembolism, erosion of adjacent structures, thrombus formation or atrial arrhythmia. This review gives an overview of the data and the current literature regarding long-term complications (follow-up > or = 1 month) after patent foramen ovale closure with current devices and presents the initial, midterm and late results after patent foramen ovale closure with newer devices.